Acute Myocarditis
10
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
64Cu-GRIP B in Patients With Acute Myocarditis
Colchicine Versus Placebo in Acute Myocarditis Patients
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity
MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis
Corticoid Therapy in Acute Myocarditis
Anakinra Versus Placebo for the Treatment of Acute MyocarditIS
Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases
German Centre for Cardiovascular Research Cardiomyopathy Register